Form 4: Exelixis Director Stelios Papadopoulos Receives Significant RSU Grant

Exelixis, Inc. Director Stelios Papadopoulos was granted 9,812 restricted stock units (RSUs) on May 29, 2025, as part of his compensation, which are set to vest in May 2026.

Summary

• Director Stelios Papadopoulos of Exelixis, Inc. (EXEL) was granted 9,812 restricted stock units (RSUs) on May 29, 2025.
• The RSUs were granted at a price of $0, which is customary for equity compensation awards.
• These RSUs are scheduled to vest 100% on May 29, 2026, contingent upon Mr. Papadopoulos's continuous service to the company.
• Following this transaction, Mr. Papadopoulos's beneficial ownership of Exelixis common stock totals 1,289,228 shares, which includes 28,650 shares from previously granted RSUs that are yet to vest.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive event as it aligns management's interests with long-term shareholder value and is a standard component of executive compensation, indicating stability and continued commitment.

Positives

• The grant of 9,812 restricted stock units (RSUs) to Director Stelios Papadopoulos aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• The one-year vesting schedule, requiring continuous service until May 29, 2026, promotes the retention of key leadership within the company.

Future Outlook

The granted restricted stock units are scheduled to vest on May 29, 2026, contingent on the director's continuous service, indicating a future milestone for this compensation.

Industry Context

This Form 4 filing represents a routine disclosure of equity compensation for a director, which is a common practice across publicly traded companies, particularly in the biotechnology sector, to align executive and board interests with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a director is a standard form of equity compensation in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance.
• The one-year vesting schedule for these RSUs is typical for such grants, comparable to practices at peer companies like Amgen, Gilead Sciences, or Biogen, which frequently utilize RSUs as a component of their executive and board compensation packages.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value, potentially leading to more focused efforts on company performance and stock appreciation.

Next Steps

• The next key event related to this grant is the vesting of the restricted stock units on May 29, 2026, assuming continuous service by the reporting person.

Key Dates

Recommendation

Keywords

Exelixis, EXEL, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity compensation, director, Stelios Papadopoulos